CL2014002258A1 - Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos. - Google Patents

Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.

Info

Publication number
CL2014002258A1
CL2014002258A1 CL2014002258A CL2014002258A CL2014002258A1 CL 2014002258 A1 CL2014002258 A1 CL 2014002258A1 CL 2014002258 A CL2014002258 A CL 2014002258A CL 2014002258 A CL2014002258 A CL 2014002258A CL 2014002258 A1 CL2014002258 A1 CL 2014002258A1
Authority
CL
Chile
Prior art keywords
mmp9
gelatinase
metalloproteinases
pharmaceutical composition
directed against
Prior art date
Application number
CL2014002258A
Other languages
English (en)
Inventor
Victoria Smith
Joanne I Ademkewicz
Zung Thai
Michael J Hawkins
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/en
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of CL2014002258A1 publication Critical patent/CL2014002258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2014002258A 2012-02-29 2014-08-26 Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos. CL2014002258A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9
US201361755444P 2013-01-22 2013-01-22

Publications (1)

Publication Number Publication Date
CL2014002258A1 true CL2014002258A1 (es) 2015-02-20

Family

ID=49003113

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002258A CL2014002258A1 (es) 2012-02-29 2014-08-26 Anticuerpos dirigidos contra metaloproteinasas de matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que lo contiene; y sus usos.

Country Status (23)

Country Link
US (2) US9732156B2 (es)
EP (2) EP2819697A4 (es)
JP (3) JP6144286B2 (es)
KR (1) KR20140130513A (es)
CN (2) CN104271156B (es)
AP (1) AP2014007921A0 (es)
AU (1) AU2013203619B2 (es)
BR (1) BR112014021081A2 (es)
CA (1) CA2865501A1 (es)
CL (1) CL2014002258A1 (es)
CO (1) CO7061039A2 (es)
CR (1) CR20140451A (es)
EA (1) EA201491599A1 (es)
EC (1) ECSP14020644A (es)
HK (4) HK1204926A1 (es)
MD (1) MD20140108A2 (es)
MX (2) MX2014010447A (es)
MY (1) MY167236A (es)
NZ (1) NZ629178A (es)
PH (1) PH12014501927A1 (es)
SG (2) SG11201405273YA (es)
WO (1) WO2013130905A1 (es)
ZA (1) ZA201406318B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2608809T1 (sl) 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
BR112014021081A2 (pt) 2012-02-29 2017-07-04 Gilead Biologics Inc anticorpos para a metaloproteinase da matriz 9
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
WO2015116820A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
AU2015223139A1 (en) * 2014-02-27 2016-08-25 Gilead Sciences, Inc. Antibodies to Matrix Metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CR20170060A (es) 2014-08-19 2017-04-18 Merck Sharp & Dohme Anticuerpos anti tigit
JP6976241B2 (ja) * 2015-08-14 2021-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗ｔｉｇｉｔ抗体
WO2017059252A1 (en) * 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
WO2017106566A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017177179A1 (en) * 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
US11162943B2 (en) 2017-05-31 2021-11-02 Prometheus Biosciences Inc. Methods for assessing mucosal healing in Crohn's disease patients
US11926655B2 (en) 2017-07-18 2024-03-12 Daiichi Sankyo Company, Limited Active MMP9-binding peptide
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
US12422441B2 (en) * 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
IL264768A (en) * 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
EP3972644A4 (en) * 2019-05-21 2024-01-10 The Regents Of The University Of California MMP-9 ANTIBODIES AND METHODS OF USE THEREOF
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
MX2022007353A (es) 2019-12-17 2022-09-19 Univ Texas Anticuerpos novedosos ddr1 y sus usos.
US20230140976A1 (en) * 2020-03-30 2023-05-11 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途
WO2025076396A1 (en) * 2023-10-04 2025-04-10 The Trustees Of The University Of Pennsylvania Methods of treating, ameliorating and/or preventing fibrodysplasia ossificans progressiva and heterotopic ossification, and kits for the same
CN117986368B (zh) * 2023-10-18 2024-11-29 深圳大学 抗肿瘤抗炎症相关的纳米抗体及其制备方法与应用
CN119060188B (zh) * 2024-08-30 2025-09-12 武汉爱博泰克生物科技有限公司 抗人基质金属蛋白酶9抗体、抗体对和检测试剂盒
CN119193495A (zh) * 2024-09-25 2024-12-27 广州通识生物医药有限公司 一种基因修饰的间充质干细胞的制备方法及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1995015374A1 (en) 1993-11-30 1995-06-08 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloprotease and dna coding for the same
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
ATE435031T1 (de) 1999-07-13 2009-07-15 Univ Southern California Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
AU2002235692A1 (en) 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
WO2003044058A2 (en) 2001-11-23 2003-05-30 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
ES2614274T3 (es) 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
ES2369498T3 (es) * 2003-04-04 2011-12-01 Yeda Research And Development Co., Ltd. Anticuerpos para inhibir la actividad de mmp-2 y mmp-9.
WO2005070966A2 (en) * 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
EP1904846A4 (en) 2005-06-29 2009-03-18 Rules Based Medicine Inc METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
CN101702906B (zh) 2007-02-23 2014-02-12 耶达研究及发展有限公司 用于抑制金属蛋白活性的抗体和含有所述抗体的药物组合物
TW200911835A (en) * 2007-06-08 2009-03-16 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
KR20100071972A (ko) 2007-08-15 2010-06-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Ｍｍｐ-9의 조절인자 및 그의 용도
EP2231186A4 (en) 2007-12-17 2012-08-08 Dyax Corp COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
EP2262529A4 (en) * 2008-03-03 2013-05-08 Dyax Corp METALLOPROTEINASE BINDING PROTEINS 9
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
AU2009308369A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
WO2011092700A1 (en) 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
SI2608809T1 (sl) 2010-08-27 2019-08-30 Gilead Biologics, Inc. Protitelesa proti matriksu metaloproteinaze 9
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
US9550836B2 (en) * 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
BR112014021081A2 (pt) 2012-02-29 2017-07-04 Gilead Biologics Inc anticorpos para a metaloproteinase da matriz 9

Also Published As

Publication number Publication date
HK1204926A1 (en) 2015-12-11
US9732156B2 (en) 2017-08-15
MX2014010447A (es) 2015-06-23
WO2013130905A1 (en) 2013-09-06
ECSP14020644A (es) 2015-09-30
MY167236A (en) 2018-08-14
ZA201406318B (en) 2016-07-27
HK1248246A1 (en) 2018-10-12
KR20140130513A (ko) 2014-11-10
SG11201405273YA (en) 2014-09-26
EP3255063A3 (en) 2018-02-07
EP2819697A1 (en) 2015-01-07
JP2015509959A (ja) 2015-04-02
US20130224210A1 (en) 2013-08-29
JP6144286B2 (ja) 2017-06-07
CN104271156B (zh) 2017-06-16
CN104271156A (zh) 2015-01-07
CR20140451A (es) 2014-11-17
MD20140108A2 (ro) 2015-03-31
AP2014007921A0 (en) 2014-09-30
EA201491599A1 (ru) 2015-05-29
MX2018007630A (es) 2023-04-12
NZ629178A (en) 2016-09-30
CA2865501A1 (en) 2013-09-06
AU2013203619B2 (en) 2015-02-26
BR112014021081A2 (pt) 2017-07-04
JP2018150343A (ja) 2018-09-27
US20180002446A1 (en) 2018-01-04
HK1244671A1 (zh) 2018-08-17
CO7061039A2 (es) 2014-09-19
AU2013203619A1 (en) 2013-09-19
PH12014501927A1 (en) 2014-11-24
SG10201610788VA (en) 2017-03-30
EP2819697A4 (en) 2016-03-09
CN107184974A (zh) 2017-09-22
EP3255063A2 (en) 2017-12-13
HK1204981A1 (en) 2015-12-11
JP2017178952A (ja) 2017-10-05
JP6343368B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
CL2014002282A1 (es) Anticuerpos contra la metaloproteinasa de la matriz 9 (mmp9 gelatinasa b); composicion farmaceutica que la contiene; y sus usos.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
CL2014002053A1 (es) Composición pesticida que comprende un compuesto derivado de una hidrazinacarbotioamida; y proceso de aplicación.
BR112015020743A2 (pt) cápsula de dose individual e sistema.
CL2014002393A1 (es) Moléculas de unión a ang2; composicion farmaceutica que las contiene; y sus usos terapeuticos.
CL2014002616A1 (es) Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
EP3661489A4 (en) COMPOSITION OF FLOTTABLE PHARMACEUTICAL MICROCAPSULE
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2016001313A1 (es) Formulaciones listas de fertilizante líquido de bifentrina.
CL2014003515A1 (es) Composición herbicida que tiene actividad herbicida mejorada.
CR20150603A (es) Metaloproteinasa de la matriz y usos del mismo
MX343035B (es) Formulacion farmaceutica novedosa que comprende nsaid y ciclodextrina.
EA033510B1 (ru) Содержащая цинеол композиция для назального применения
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
CL2014003135A1 (es) Formulacion que comprende un quelato de oligonucleotidos; y sus usos.
CO7160079A2 (es) Composiciones líquidas de racecadotrillo